Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
24 10 2023
24 10 2023
Historique:
received:
05
04
2023
accepted:
10
10
2023
medline:
26
10
2023
pubmed:
25
10
2023
entrez:
24
10
2023
Statut:
epublish
Résumé
Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which predicts response to immunotherapy in many cancer types. In this prospective, non-randomized, open-label, multicenter Phase II trial (EudraCT 2018-004562-33; NCT04131621), patients relapsed or refractory after platinum-based chemotherapy received nivolumab and ipilimumab following TMB
Identifiants
pubmed: 37875494
doi: 10.1038/s41467-023-42400-5
pii: 10.1038/s41467-023-42400-5
pmc: PMC10598029
doi:
Substances chimiques
Nivolumab
31YO63LBSN
Ipilimumab
0
Banques de données
EudraCT
['EudraCT 2018-004562-33']
ClinicalTrials.gov
['NCT04131621']
Types de publication
Clinical Trial, Phase II
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6761Informations de copyright
© 2023. Springer Nature Limited.
Références
Ann Oncol. 2023 Mar;34(3):228-246
pubmed: 36563965
Cancer Invest. 2001;19(4):335-9
pubmed: 11405172
Clin Cancer Res. 2018 Oct 15;24(20):4960-4967
pubmed: 29685882
Eur J Cancer. 2012 Mar;48(5):721-7
pubmed: 22317952
Nat Commun. 2021 Sep 23;12(1):5606
pubmed: 34556668
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
J Clin Oncol. 2003 Sep 15;21(18):3479-82
pubmed: 12972523
Ann Oncol. 2022 Feb;33(2):216-226
pubmed: 34843940
J Clin Epidemiol. 2011 Dec;64(12):1464-5; author reply 1463-4
pubmed: 22032755
Clin Cancer Res. 2017 Jun 15;23(12):3012-3024
pubmed: 28039262
Cancer. 2006 Dec 15;107(12):2898-905
pubmed: 17109447
Sci Rep. 2022 Aug 22;12(1):14319
pubmed: 35996017
J Biotechnol. 2017 Nov 10;261:53-62
pubmed: 28803971
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Oncoimmunology. 2021 Jan 11;10(1):1860586
pubmed: 33520406
Oncologist. 2021 May;26(5):e769-e779
pubmed: 33687747
Int J Cancer. 2019 Aug 1;145(3):649-661
pubmed: 30653256
Nat Rev Neurosci. 2013 May;14(5):365-76
pubmed: 23571845
Ann Oncol. 2020 Jun;31(6):807-814
pubmed: 32171752
Nat Med. 2022 Nov;28(11):2353-2363
pubmed: 36357680
Cancer Cell. 2018 Apr 9;33(4):676-689.e3
pubmed: 29622463
Neoplasia. 2021 Sep 20;23(10):1059-1068
pubmed: 34555656
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
J Thorac Oncol. 2022 Mar;17(3):399-410
pubmed: 34740862
J Mol Diagn. 2020 Jun;22(6):757-769
pubmed: 32205293
Anticancer Res. 2001 Mar-Apr;21(2B):1455-7
pubmed: 11396231
J Immunother Cancer. 2017 Feb 21;5:18
pubmed: 28239471
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35264433
J Natl Cancer Inst. 2018 Jun 1;110(6):677-681
pubmed: 29917141
Nucleic Acids Res. 2013 May 1;41(10):e108
pubmed: 23558742
Front Mol Biosci. 2020 Nov 19;7:602328
pubmed: 33330629
JCO Precis Oncol. 2022 Jul;6:e2100512
pubmed: 35834760
EBioMedicine. 2019 Mar;41:711-716
pubmed: 30852159
Cancer. 2020 Mar 15;126(6):1208-1216
pubmed: 31829450
Oncotarget. 2016 Jul 12;7(28):44322-44329
pubmed: 27322425
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
J Clin Oncol. 2023 Mar 20;41(9):1684-1694
pubmed: 36542815
Br J Cancer. 2009 Jan 13;100(1):44-9
pubmed: 19066607
J Clin Oncol. 2019 Mar 1;37(7):570-579
pubmed: 30653423
Oncologist. 2021 Mar;26(3):e394-e402
pubmed: 33219618
JAMA Oncol. 2023 Oct 1;9(10):1441-1446
pubmed: 37651124
Cancer. 2020 May 15;126(10):2288-2295
pubmed: 32142165
J Thorac Oncol. 2020 Jul;15(7):1177-1189
pubmed: 32119917
Anticancer Res. 2019 Feb;39(2):815-825
pubmed: 30711962
Br J Cancer. 2021 Feb;124(4):721-727
pubmed: 33235314
Nat Genet. 2021 Jan;53(1):11-15
pubmed: 33398197
Nat Genet. 2022 Dec;54(12):1782-1785
pubmed: 36443443
Cancer. 2005 Nov 1;104(9):1992-7
pubmed: 16130138
Cancer Cell. 2018 May 14;33(5):843-852.e4
pubmed: 29657128
Cancer J. 2010 Jan-Feb;16(1):70-5
pubmed: 20164695
JAMA Netw Open. 2021 Feb 1;4(2):e2037120
pubmed: 33570575
Cancer. 2010 May 15;116(10):2448-54
pubmed: 20209610
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Ann Oncol. 2022 Sep;33(9):984-985
pubmed: 35636622
Acta Oncol. 2010 May;49(4):431-5
pubmed: 20235750
Int J Cancer. 2020 Jun 1;146(11):3053-3064
pubmed: 31970771
Eur J Cancer. 2018 May;94:179-186
pubmed: 29571084
Genome Res. 2017 Mar;27(3):491-499
pubmed: 28100584
Genes Chromosomes Cancer. 2022 Sep;61(9):551-560
pubmed: 35430765
J Clin Oncol. 2018 Jun 10;36(17):1685-1694
pubmed: 29489427
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Immunother Cancer. 2022 May;10(5):
pubmed: 35618285
Clin Cancer Res. 2020 Aug 1;26(15):4135-4142
pubmed: 32332016
Cancer. 2015 May 15;121(10):1654-61
pubmed: 25611313
Clin Lung Cancer. 2020 Sep;21(5):e405-e414
pubmed: 32205040
Biometrics. 1986 Sep;42(3):507-19
pubmed: 3567285
J Clin Oncol. 2023 Feb 20;41(6):1200-1212
pubmed: 36223558
Auris Nasus Larynx. 2020 Aug;47(4):650-657
pubmed: 32035695
Nat Cancer. 2022 Nov;3(11):1367-1385
pubmed: 36344707
J Clin Oncol. 2007 May 1;25(13):1747-52
pubmed: 17470864
Oncologist. 2020 Sep;25(9):803-809
pubmed: 32369650
Nat Med. 2022 Aug;28(8):1612-1618
pubmed: 35915157
Oncotarget. 2017 Jul 25;8(41):71249-71284
pubmed: 29050360
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137